A Phase 1, Randomised, Single-centre, Open-Label, Cross-Over, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability Following Administration of IPN60170 in Healthy Japanese, Chinese and Non-Asian Participants - Global

A Phase 1, Randomised, Single-centre, Open-Label, Cross-Over, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability Following Administration of IPN60170 in Healthy Japanese, Chinese and Non-Asian Participants

- 20 November 2023 - 1 mins read

A Phase 1, Randomised, Single-centre, Open-Label, Cross-Over, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability Following Administration of IPN60170 in Healthy Japanese, Chinese and Non-Asian Participants

IPN60170